Back

Palatin advances MC4R agonists for rare obesity disorders

Verifying
  • Palatin Technologies is advancing selective MC4R agonist programs for rare obesity disorders.
  • The company plans Phase 1 trials for a once-weekly injectable program.
  • Target conditions include hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.